Human Liver Model Market Size, Share & Trends Analysis Report By Product (2D Models, 3D Models), By Application (ADME Studies, Toxicology Testing), By End Use, By Region, And Segment Forecasts, 2025 - 2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,950	120 Pages	Grand View Research	January, 2025	GV19584322

Best Price Guarantee
Price	from $5,950
Length	120 Pages
Publisher	Grand View Research
Published Date	January, 2025
SKU	GV19584322

Table of Contents
Description

Human Liver Model Market Size & Trends

The global human liver model market size was valued at USD 1.34 billion in 2024 and is projected to grow at a CAGR of 14.04% from 2025 to 2030. The industry is driven by the increasing prevalence of liver diseases, advancements in organ printing technologies, and increased demand for therapeutic drugs for liver cancer, which is expected to propel its growth.

According to the Health Resources & Services Administration, in 2023, in the U.S., 106,800 individuals are waiting for organ transplants. The healthcare landscape is evolving, and advancements in 3D printing technology are set to transform healthcare by addressing organ shortages and improving patient care globally.

The prevalence of liver diseases is on the rise globally, leading to a growing demand for advanced research tools, including human liver models. Chronic liver conditions such as non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, viral hepatitis, and liver cancer are becoming increasingly common due to factors such as unhealthy diets, sedentary lifestyles, alcohol consumption, and viral infections. For instance, NAFLD emerged as the most prevalent chronic liver disorder in Western countries, affecting approximately 25% of the global population. This significant rise in the prevalence of liver diseases has driven the urgent need for more accurate and efficient human liver models to support research and drug development efforts.

rgan 3D printing technologies have advanced significantly recently, particularly in developing human liver models. These advancements have revolutionized regenerative medicine and drug testing by providing more accurate and personalized models for research purposes. For instance, in February 2023, researchers at the University of California San Diego made significant progress in addressing challenging issues in bio-printing 3D-engineered tissues, achieving high cell density, viability, and precise fabrication resolution.

Global Human Liver Model Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global human liver model market report on the basis of product, application, end-use, and region.

Product Outlook (Revenue, USD Million, 2018 - 2030)
2D Models

Cell lines

Primary Cells

3D Models

Liver on Chip

Organoids

Spheroids

Others

Application Outlook (Revenue, USD Million, 2018 - 2030)
ADME Studies
Toxicology Testing
Disease Modelling
Others
End Use Outlook (Revenue, USD Million, 2018 - 2030)
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America

U.S.

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Brazil

Argentina

Middle East and Africa

South Africa

Saudi Arabia

UAE

Kuwait

Please note The report will be delivered in 2-3 business days upon order notification.

Chapter 1. Methodology and Scope: 1.1. Market Segmentation & Scope; 1.2. Segment Definitions; 1.2.1. Product; 1.2.2. Application; 1.2.3. End-use; 1.3. Research Methodology; 1.4. Information Procurement; 1.4.1. Purchased database; 1.4.2. GVR’s internal database; 1.4.3. Secondary sources; 1.4.4. Primary research; 1.4.5. Details of primary research; 1.5. Information or Data Analysis; 1.5.1. Data analysis models; 1.6. Market Formulation & Validation; 1.7. Model Details; 1.7.1. Commodity flow analysis (Model 1); 1.7.2. Approach 1: Commodity flow approach; 1.8. List of Secondary Sources; 1.9. List of Primary Sources; 1.10. Objectives
Chapter 2. Executive Summary: 2.1. Market Outlook; 2.2. Segment Snapshot; 2.3. Competitive Landscape Snapshot
Chapter 3. Human Liver Model Market Variables, Trends & Scope: 3.1. Market Lineage Outlook; 3.1.1. Parent market outlook; 3.1.2. Related/ancillary market outlook.; 3.2. Market Dynamics; 3.2.1. Market driver analysis; 3.2.1.1. Increasing prevalence of liver diseases; 3.2.1.2. Advancements in organ printing technologies; 3.2.1.3. Increased demand for therapeutic drugs for liver cancer; 3.2.2. Market restraint analysis; 3.2.2.1. High costs and complexity associated with maintaining human liver models; 3.3. Human Liver Model Market Analysis Tools; 3.3.1. Industry Analysis – Porter’s; 3.3.2. PESTEL Analysis; 3.3.3. COVID-19 Impact Analysis
Chapter 4. Human Liver Model Market: Product Estimates & Trend Analysis: 4.1. Product Segment Dashboard; 4.2. Global Human Liver Model Market Product Movement Analysis, 2024 & 2030 (USD Million); 4.3. Global Human Liver Model Market Size and Trend Analysis, by Product, 2018 to 2030 (USD Million); 4.4. 2D Models; 4.4.1. 2D models market estimates and forecasts 2018 to 2030 (USD Million); 4.4.2. Cell Lines; 4.4.2.1. Cell Lines market estimates and forecasts 2018 to 2030 (USD Million); 4.4.3. Primary Cells; 4.4.3.1. Primary Cells market estimates and forecasts 2018 to 2030 (USD Million); 4.5. 3D Models; 4.5.1. 3D models market estimates and forecasts 2018 to 2030 (USD Million); 4.5.2. Liver on Chip; 4.5.2.1. Liver on Chip market estimates and forecasts 2018 to 2030 (USD Million); 4.5.3. Organoids; 4.5.3.1. Organoids market estimates and forecasts 2018 to 2030 (USD Million); 4.5.4. Spheroids; 4.5.4.1. Spheroids market estimates and forecasts 2018 to 2030 (USD Million); 4.5.5. Others; 4.5.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Human Liver Model Market: Application Estimates & Trend Analysis: 5.1. Application Segment Dashboard; 5.2. Global Human Liver Model Market Application Movement Analysis, 2024 & 2030 (USD Million); 5.3. Global Human Liver Model Market Size and Trend Analysis, by Application, 2018 to 2030 (USD Million); 5.4. ADME Studies; 5.4.1. ADME Studies market estimates and forecasts 2018 to 2030 (USD Million); 5.5. Toxicology Testing; 5.5.1. Toxicology Testing market estimates and forecasts 2018 to 2030 (USD Million); 5.6. Disease Modelling; 5.6.1. Disease Modelling market estimates and forecasts 2018 to 2030 (USD Million); 5.7. Others; 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Human Liver Model Market: End-use Estimates & Trend Analysis: 6.1. End-use Segment Dashboard; 6.2. Global Human Liver Model Market End-use Movement Analysis, 2024 & 2030 (USD Million); 6.3. Global Human Liver Model Market Size and Trend Analysis, by End-use, 2018 to 2030 (USD Million); 6.4. Academic & Research Institutes; 6.4.1. Academic & Research Institutes market estimates and forecasts 2018 to 2030 (USD Million); 6.5. Pharmaceutical & Bioproduct Companies; 6.5.1. Pharmaceutical & Bioproduct Companies market estimates and forecasts 2018 to 2030 (USD Million); 6.6. Contract Research Organizations; 6.6.1. Contract Research Organizations market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Human Liver Model Market: Regional Estimates & Trend Analysis: 7.1. Human Liver Model Market: Regional Estimates & Trend Analysis by Product, Application, and End-use; 7.2. Regional Market Dashboard; 7.3. Regional Market Share Analysis, 2024 & 2030; 7.4. North America; 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million); 7.4.2. U.S.; 7.4.2.1. Key country dynamics; 7.4.2.2. Competitive scenario; 7.4.2.3. U.S. market estimates and forecasts 2018 to 2030 (USD Million); 7.4.3. Canada; 7.4.3.1. Key country dynamics; 7.4.3.2. Competitive scenario; 7.4.3.3. Canada market estimates and forecasts 2018 to 2030 (USD Million); 7.4.4. Mexico; 7.4.4.1. Key country dynamics; 7.4.4.2. Competitive scenario; 7.4.4.3. Mexico market estimates and forecasts 2018 to 2030 (USD Million); 7.5. Europe; 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million); 7.5.2. UK; 7.5.2.1. Key country dynamics; 7.5.2.2. Competitive scenario; 7.5.2.3. UK market estimates and forecasts 2018 to 2030 (USD Million); 7.5.3. Germany; 7.5.3.1. Key country dynamics; 7.5.3.2. Competitive scenario; 7.5.3.3. Germany market estimates and forecasts 2018 to 2030 (USD Million); 7.5.4. France; 7.5.4.1. Key country dynamics; 7.5.4.2. Competitive scenario; 7.5.4.3. France market estimates and forecasts 2018 to 2030 (USD Million); 7.5.5. Italy; 7.5.5.1. Key country dynamics; 7.5.5.2. Competitive scenario; 7.5.5.3. Italy market estimates and forecasts 2018 to 2030 (USD Million); 7.5.6. Spain; 7.5.6.1. Key country dynamics; 7.5.6.2. Competitive scenario; 7.5.6.3. Spain market estimates and forecasts 2018 to 2030 (USD Million); 7.5.7. Denmark; 7.5.7.1. Key country dynamics; 7.5.7.2. Competitive scenario; 7.5.7.3. Denmark market estimates and forecasts 2018 to 2030 (USD Million); 7.5.8. Sweden; 7.5.8.1. Key country dynamics; 7.5.8.2. Competitive scenario; 7.5.8.3. Sweden market estimates and forecasts 2018 to 2030 (USD Million); 7.5.9. Norway; 7.5.9.1. Key country dynamics; 7.5.9.2. Competitive scenario; 7.5.9.3. Norway market estimates and forecasts 2018 to 2030 (USD Million); 7.6. Asia Pacific; 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million); 7.6.2. Japan; 7.6.2.1. Key country dynamics; 7.6.2.2. Competitive scenario; 7.6.2.3. Japan market estimates and forecasts 2018 to 2030 (USD Million); 7.6.3. China; 7.6.3.1. Key country dynamics; 7.6.3.2. Competitive scenario; 7.6.3.3. China market estimates and forecasts 2018 to 2030 (USD Million); 7.6.4. India; 7.6.4.1. Key country dynamics; 7.6.4.2. Competitive scenario; 7.6.4.3. India market estimates and forecasts 2018 to 2030 (USD Million); 7.6.5. Australia; 7.6.5.1. Key country dynamics; 7.6.5.2. Competitive scenario; 7.6.5.3. Australia market estimates and forecasts 2018 to 2030 (USD Million); 7.6.6. South Korea; 7.6.6.1. Key country dynamics; 7.6.6.2. Competitive scenario; 7.6.6.3. South Korea market estimates and forecasts 2018 to 2030 (USD Million); 7.6.7. Thailand; 7.6.7.1. Key country dynamics; 7.6.7.2. Competitive scenario; 7.6.7.3. Thailand market estimates and forecasts 2018 to 2030 (USD Million); 7.7. Latin America; 7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million); 7.7.2. Brazil; 7.7.2.1. Key country dynamics; 7.7.2.2. Competitive scenario; 7.7.2.3. Brazil market estimates and forecasts 2018 to 2030 (USD Million); 7.7.3. Argentina; 7.7.3.1. Key country dynamics; 7.7.3.2. Competitive scenario; 7.7.3.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million); 7.8. MEA; 7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million); 7.8.2. South Africa; 7.8.2.1. Key country dynamics; 7.8.2.2. Competitive scenario; 7.8.2.3. South Africa market estimates and forecasts 2018 to 2030 (USD Million); 7.8.3. Saudi Arabia; 7.8.3.1. Key country dynamics; 7.8.3.2. Competitive scenario; 7.8.3.3. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million); 7.8.4. UAE; 7.8.4.1. Key country dynamics; 7.8.4.2. Competitive scenario; 7.8.4.3. UAE market estimates and forecasts 2018 to 2030 (USD Million); 7.8.5. Kuwait; 7.8.5.1. Key country dynamics; 7.8.5.2. Competitive scenario; 7.8.5.3. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape: 8.1. Company/Competition Categorization; 8.2. Strategy Mapping; 8.3. Company Market Position Analysis, 2024; 8.4. Company Profiles; 8.4.1. ATCC; 8.4.1.1. Company overview; 8.4.1.2. Financial performance; 8.4.1.3. Product benchmarking; 8.4.1.4. Strategic initiatives; 8.4.2. Merck KGaA; 8.4.2.1. Company overview; 8.4.2.2. Financial performance; 8.4.2.3. Product benchmarking; 8.4.2.4. Strategic initiatives; 8.4.3. AcceGen; 8.4.3.1. Company overview; 8.4.3.2. Financial performance; 8.4.3.3. Product benchmarking; 8.4.3.4. Strategic initiatives; 8.4.4. ZenBio, Inc.; 8.4.4.1. Company overview; 8.4.4.2. Financial performance; 8.4.4.3. Product benchmarking; 8.4.4.4. Strategic initiatives; 8.4.5. Organovo Holdings Inc.; 8.4.5.1. Company overview; 8.4.5.2. Financial performance; 8.4.5.3. Product benchmarking; 8.4.5.4. Strategic initiatives; 8.4.6. BioIVT; 8.4.6.1. Company overview; 8.4.6.2. Financial performance; 8.4.6.3. Product benchmarking; 8.4.6.4. Strategic initiatives; 8.4.7. InSphero; 8.4.7.1. Company overview; 8.4.7.2. Financial performance; 8.4.7.3. Product benchmarking; 8.4.7.4. Strategic initiatives; 8.4.8. Emulate, Inc.; 8.4.8.1. Company overview; 8.4.8.2. Financial performance; 8.4.8.3. Product benchmarking; 8.4.8.4. Strategic initiatives; 8.4.9. Mimetas; 8.4.9.1. Company overview; 8.4.9.2. Financial performance; 8.4.9.3. Product benchmarking; 8.4.9.4. Strategic initiatives; 8.4.10. CN Bio Innovations Ltd; 8.4.10.1. Company overview; 8.4.10.2. Financial performance; 8.4.10.3. Product benchmarking; 8.4.10.4. Strategic initiatives